Artificial Intelligence (AI) in Clinical Trials Global Market Report 2024

The artificial intelligence (AI) in clinical trials market size has grown exponentially in recent years. It will grow from $1.52 billion in 2023 to $1.95 billion in 2024 at a compound annual growth rate (CAGR) of 28.1%. The historical period's growth can be ascribed to factors such as the escalating complexity of data, heightened costs and time limitations, regulatory requirements, early applications of AI, and the adoption of patient-centric approaches.

The artificial intelligence (AI) in clinical trials market size is expected to see exponential growth in the next few years. It will grow to $4.86 billion in 2028 at a compound annual growth rate (CAGR) of 25.6%. The anticipated growth in the forecast period is linked to the emphasis on personalized medicine, the implementation of real-time monitoring solutions, remote execution of trials, prediction and mitigation of risks, and the integration of expanded data sources. Key trends expected in the forecast period encompass adaptive trial design, the application of natural language processing (NLP) in data analysis, AI-driven patient recruitment, the integration of blockchain for data security, and the utilization of predictive analytics for assessing patient outcomes.

The anticipated growth in the artificial intelligence clinical trial market is driven by the growing imperative to control clinical trial costs. Clinical trials, which evaluate medical, surgical, or behavioral interventions in individuals, incur expenses related to research and patient care. The inherently costly nature of drug development and other clinical trial processes has led to the application of artificial intelligence for more efficient drug discovery, the creation of better-designed and safer clinical trials, and improved patient outcomes - all at reduced costs. For instance, a February 2023 report from Genetic Engineering and Biotechnology News highlighted a 15% increase in the cost of developing a new drug among the top 20 global biopharma companies, rising from $298 million in 2022 to approximately $2.3 billion in 2023. This cost encompasses expenses incurred during drug development, including clinical trials. Additionally, a January 2023 report from the National Bureau of Economic Research projected significant cost savings in healthcare - ranging from 5 to 10% of healthcare spending, translating to approximately $200 billion to $360 billion in annual savings - attributed to the adoption of AI within the next five years. Hence, the imperative to control clinical trial costs is expected to drive the artificial intelligence clinical trial market.

The factor expected to drive the growth of artificial intelligence in the clinical trial market is the increasing volume of research and development activities. Research and Development (R&D) activities involve a systematic process of investigation, experimentation, and innovation conducted by organizations or individuals to create new products, processes, or knowledge. Artificial Intelligence (AI) significantly contributes to various facets of R&D activities in the context of clinical trials, including the analysis of diverse datasets, implementation of adaptive trial designs, and streamlining administrative processes. For instance, a May 2023 report from Xtalks noted an increase in the R&D pipeline for drugs from 18,582 in 2021 to over 20,109 drugs in 2022. Furthermore, the global count of registered clinical trials surged to 452,604 in 2023, marking a substantial rise from the reported figure of over 365,000 trials in 2021. Consequently, the escalating number of research and development activities is expected to propel the artificial intelligence clinical trial market's growth.


An emerging trend in the artificial intelligence in clinical trial market is the introduction of innovative product offerings. Leading companies in this market have unveiled novel products to maintain their competitive standing. For example, in January 2023, Elligo Health Research Inc., a healthcare-enabling research organization based in the US, rolled out DataAI Connect. This groundbreaking data and technology platform facilitate swift, data-driven clinical research by seamlessly collecting, managing, evaluating, and sharing real-world patient data. unlike as mere supplementary technology, this adaptable and sustainable platform presents a comprehensive strategy to overcome clinical trial challenges. It features an all-in-one solution for retrieving and assessing medical records, utilizing cutting-edge technologies such as Natural Language Processing (NLP), Machine Learning (ML), and clinical expertise to transform data into actionable insights and individual patient progress information.

Major players in the artificial intelligence in clinical trials market are directing their efforts toward developing innovative technologies such as AI feasibility and recruitment platforms. These platforms leverage artificial intelligence (AI) to evaluate the viability and potential success of clinical trials, while also aiding in the efficient recruitment of suitable participants. For instance, in June 2023, a US-based research provider company unveiled 'ObjectiveScreen,' an AI-powered feasibility and recruitment platform that enhances clinical trial performance and outcomes by improving patient identification, prequalification, and retention processes. ObjectiveScreen establishes direct connectivity between clinical trial sites and the electronic health records (EHRs) of patients, promoting patient engagement through simplified and streamlined appointment scheduling and communication processes.

In January 2023, Paradigm Health Inc., a US-based healthcare technology company, acquired Deep Lens Inc. The acquisition is geared towards providing Paradigm with Deep Lens's platform, which ensures equal access to trials for all patients while enhancing trial efficiency and reducing barriers to participation for healthcare providers. Deep Lens Inc., based in the US, is a provider of an AI-driven cloud platform for clinical research.

Major companies operating in the artificial intelligence (AI) in clinical trials market report are Medable Inc., PathAI Inc., Saama Technologies Inc., Apellis Pharmaceuticals Inc., TriNetX LLC, SymphonyAI Summit Inc., Aktana, Nference Inc., Insilico Medicine Inc., Vineti Inc., Innoplexus AG, Healx, AiCure Inc., MEDIAN Technologies SA, Owkin Inc., Science 37, Ardigen SA, Cyft Inc., Unlearn.AI Inc., Mendel AI, Deep Lens Inc., Antidote Technologies Inc., Arterys Inc., Euretos BV, Halo Health Systems Inc., Trials.AI Inc., Transparency Life Sciences, BioAge Labs Inc., Wave Life Sciences Ltd., BioSymetrics Inc.

North America was the largest region in the artificial intelligence (AI) in clinical trials market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) in clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary offerings of AI in clinical trials encompass both software and services. Software solutions involve the development or configuration of customized solutions to address specific challenges. Artificial intelligence software is utilized to facilitate quicker and more accurate hypothesis generation and to gain insights into disease progression. These applications extend to various stages of the clinical trial process, including trial design, patient selection, site selection, and patient monitoring across a range of medical fields such as oncology, neurological diseases, cardiovascular diseases, metabolic diseases, infectious diseases, and immunology diseases. The beneficiaries of AI in clinical trials include pharmaceutical and biotechnology companies, contract research organizations, and other relevant stakeholders.

The artificial intelligence (AI) in clinical trials research report is one of a series of new reports that provides artificial intelligence (AI) in clinical trials market statistics, including the artificial intelligence (AI) in clinical trials industry's global market size, regional shares, competitors with an artificial intelligence (AI) in clinical trials market share, detailed artificial intelligence (AI) in clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in clinical trials industry. This artificial intelligence (AI) in clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The artificial intelligence (AI) in clinical trials market consists of revenues earned by entities by providing artificial intelligence in clinical trials services that include data security and compliance services and consulting and implementation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in the clinical trials market also includes sales of clinical trial matching software, patient recruitment software and medical image analysis software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.